Sina Vahedi, MD
Glaucoma Specialist · Sacramento, CANPI 1679005219
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,520 of the $2,413 with a category attached, or 63.0%. 13 manufacturers reported payments, led by AbbVie at 55.6% of the total. Reporting peaked in 2023 at $1,206 and has fallen 88.0% since, to $144 in 2025. That places this record below the midpoint for glaucoma specialist clinicians in CA, where the typical reported total is $4,143.
Across 40 payments — averaging $60.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$335
- Sight Sciences, Inc.$132
- Mallinckrodt Enterprises LLC$119
- Sun Pharmaceutical Industries Inc.$109
- Regeneron Healthcare Solutions, Inc.$81
- plus $295 from 7 others
What the payments were for
- Travel & lodging$89337%
- Food & beverage$1,52063%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 13 | $1,343 |
| Alcon | 7 | $335 |
| Sight Sciences, Inc. | 1 | $132 |
| Mallinckrodt Enterprises LLC | 1 | $119 |
| Sun Pharmaceutical Industries Inc. | 4 | $109 |
| Regeneron Healthcare Solutions, Inc. | 1 | $81 |
| Glaukos Corporation | 2 | $71 |
| Novartis | 3 | $62 |
| Bausch & Lomb Americas Inc. | 3 | $59 |
| Eyevance Pharmaceuticals LLC | 2 | $37 |
| Amgen | 1 | $26 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $22 |
| Dompe US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$893
- Hydrus Microstent$144
- OMNI(R) SURGICAL SYSTEM (US)$132
- LUMIGAN$124
- XEN GLAUCOMA TREATMENT SYSTEM$123
- ACTHAR$119
How this compares
$2,413 in reported general payments places this provider in the 40th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 21 | $10,340 |
| Prednisolone Acetate | 88 | $4,368 |
| Latanoprost | 128 | $2,665 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 94 | $2,446 |
| Brimonidine Tartrate | 64 | $1,330 |
| Ketorolac Tromethamine | 29 | $522 |
| Timolol Maleate | 37 | $482 |
| Ofloxacin | 38 | $436 |
| Dorzolamide Hcl | 19 | $359 |
| MoxifloxacinMoxifloxacin Hcl | 14 | $196 |
Paid to pharmacies, not to this prescriber.
Other glaucoma specialist in Sacramento
- Jacob BrubakerSacramento$229K
- Tessnim AhmadSacramento$1K
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.